Roy A. Jensen, MD, has been the director of The University of Kansas Cancer Center since 2004. That year, he was also appointed the William R. Jewell, M.D. Distinguished Kansas Masonic Professor, the director of the Kansas Masonic Research Institute, professor of pathology and laboratory medicine, and professor of anatomy and cell biology at the University of Kansas Medical Center. Under his leadership, KU Cancer Center earned designation as a National Cancer Institute cancer center in 2012.

With over 150 scientific publications, Dr. Jensen has lectured widely on the clinical and molecular aspects of breast cancer pathology. His research focuses on understanding the function of BRCA1 and BRCA2 and their role in breast and ovarian neoplasia; and on the characterization of premalignant breast disease.

A member of AACI's board of directors since 2013, Dr. Jensen chaired the association's 2013 program committee.

AACI Board of Directors

For over four decades, cancer centers have worked together to lower cancer incidence and mortality rates through research and sound public policy. Such efforts can save hundreds—if not thousands—of lives over many years and represent a critical tool for lowering cancer mortality.

AACI has an unprecedented opportunity to exert enormous influence on public policy, leveraging the collective efforts of its 98 cancer centers across North America for maximum impact.

For his presidential initiative, Dr. Roy Jensen will spearhead the development of a comprehensive, cancer-specific library of model legislation that is thoroughly vetted and customizable.

Inspired by successful efforts at KU Cancer Center and the work of national cancer advocacy organizations, Dr. Jensen will launch a web-based hub of model policies to address issues ranging from oral chemotherapy parity and radon legislation to coverage of routine care for clinical trials.
 

Read More